Abstract:Abstract BACKGROUND: Leuprorelin (Enantone®) is a gonadotropin-releasing hormone (GnRH) analogue used worldwide to treat central precocious puberty (CPP). This clinical trial aimed to evaluate the long-term safety and efficacy of leuprorelin in treating Chinese CPP children. Methods: This is the first, prospective, open-label, and multicenter study conducted from 2015 to 2018, in China. As a large interventional study, it included a four-week screening period, a 96-week treatment period, and a four-week safety follow-up period. Eligible subjects were treated with leuprorelin subcutaneously once every four weeks for 96 weeks. At the beginning of the study, subjects whose body weight ≥20 kg received a dose of 3.75 mg and those <20 kg received a dose of 1.88 mg and then the dose was allowed to be adjusted during the study based on subject’s condition and investigator’s judgment. The primary endpoint was the incidence of adverse events during treatment, and the secondary endpoint was the percentage of subjects who had regression or no progression in Tanner stage at Week 96 compared with baseline. Results: A total of 307 CPP patients from 11 Chinese medical centers received leuprorelin, of which 305 (99.3%) were girls and 2 were boys (0.7%), with a mean (±SD) age of 7.95±0.982 years and a mean height of 133.68±7.108 cm. Two hundred eighty-three (92.2%) patients completed the 96-week treatment period. Two hundred fifty-two patients (82.1%) reported treatment-emergent adverse events (TEAEs)—most of which (79.5%) were mild to moderate. Only 33 (10.7%) patients experienced TEAEs that were considered related to leuprorelin. The most frequent (>2%) drug-related TEAEs were injection site induration (4.6%, 14/307) and vaginal bleeding (2.3%, 7/305). After the 96-week treatment period, 83.5% female subjects had regression or no progression in Tanner stage compared with baseline (95% CI: 78.68%, 87.62%) and the 2 male subjects had progression of 1 point in Tanner stage genital score occurred at Week 12 and then remained stable throughout the study. By the end of the treatment period, the majority of subjects had decreased GnRH stimulated peak LH and FSH, as well as reduced sex hormone levels and bone age/chronological age ratio compared with baseline. The subjects also had increased predicted adult height and BMI after treatment. Conclusions: This Chinese study demonstrated that CPP was effectively treated in most patients who received leuprorelin (Enantone®) for nearly two years. Any drug-related adverse events were reported with low incidence (<5%) and were consistent with the known safety profile of leuprorelin. Leuprorelin was shown to be well tolerated and effective in the management of CPP in Chinese patients.

Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast Puberty in Chinese Girls

Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty]

[Long-Acting Gonadotropin-Releasing Hormone Analogue in Treatment of Idiopathic Central Precocious Puberty in Girls].

[Impact of Gonadotropin-Releasing Hormone Analogs on Body Mass Index in Girls with Idiopathic Central Precocious Puberty: a Long-Term Follow-Up Study].

Long-term effects of GnRHa on central precocious puberty or early and fast puberty children

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age.

SUN-094 Long-Term Safety and Efficacy of Leuprorelin in Treating Central Precocious Puberty: A Large, Open-Label, Multicenter, Phase IV Study in China

Application of gonadotropin-releasing hormone analogues in children with central precocious puberty

Effects of gonadotropin releasing hormone analogue treatment on final adult height in girls with idiopathic central precocious puberty or advanced puberty

Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study

Effects of Gonadotropin-Releasing Hormone Analogs on Height in Girls with Idiopathic Central Precocious Puberty

Gonadotropin Releasing Hormone Agonist Treatment to Increase Final Stature in Children with Precocious Puberty: a Meta-Analysis.

Effect of Gonadotropin-Releasing Hormone Analogue Treatment on Body Mass Index in Central Precocious Puberty or Early and Fast Puberty Girls

Final adult height and side effects of gonadotropin releasing hormone analogue treatment in 23 girls with idiopathic central precocious puberty

An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children

Effects of Treatment on Female Idiopathic Central Precious Puberty with Gonodotrophine-Releasing Hormone Analogue and Growth Hormone.

Effect of Combined Treatment with GnRHa and GH on Linear Growth in Mid-and Late Pubertal Girls at Great Bone Ages with CPP or EFP and Rela-Tion to CNP Signaling Pathway

Is a Combination of a GnRH Agonist and Recombinant Growth Hormone an Effective Treatment to Increase the Final Adult Height of Girls with Precocious or Early Puberty?

Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life

Retrospective evaluation of patients diagnosed with central precocious puberty who reached the final height

Efficacy of Treatment with Gonadotropin-Releasing Hormone Analogue Alone or Combined with Recombinant Human Growth Hormone in Pubertal Short Children